Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 04 2021
Historique:
received: 21 10 2020
accepted: 19 03 2021
entrez: 14 4 2021
pubmed: 15 4 2021
medline: 5 11 2021
Statut: epublish

Résumé

Gastrointestinal symptoms are frequent in acute adrenal insufficiency. Although digestive symptoms can significantly reduce quality of life, they are rarely described in patients with treated chronic adrenal insufficiency (CAI). We aimed to characterize digestive symptoms in CAI patients. We used the section pertaining functional bowel disorders of the Rome IV questionnaire. A questionnaire was published on the website of the non-profit patient association "Adrenals" (NPPA of CAI patients) for five months. Information on demographics, characteristics of adrenal insufficiency, digestive symptoms and quality of life was collected. The relatives of CAI patients served as a control group. We analyzed responses of 33 control subjects and 119 patients (68 primary adrenal insufficiency (PAI), 30 secondary adrenal insufficiency (SAI) and 21 congenital adrenal hyperplasia (CAH)). Abdominal pain at least once a week over the past 3 months was reported by 40%, 47% and 33% of patients with PAI, SAI and CAH respectively versus 15% for the controls (p = 0.01). Symptoms were consistent with the Rome IV criteria for irritable bowel syndrome in 27%, 33% and 33% of patients respectively versus 6% for the controls (p < 0.0001). Quality of life was described as poor or very poor in 35%, 57% and 24% of patients respectively versus 5% for the controls (p < 0.0001). In conclusion, digestive symptoms are frequent and incapacitating in CAI patients and similar to symptoms of irritable bowel syndrome in 30% of CAI patients. Assessment and management of digestive symptoms should be considered a priority for physicians treating patients with CAI.

Identifiants

pubmed: 33850177
doi: 10.1038/s41598-021-87158-2
pii: 10.1038/s41598-021-87158-2
pmc: PMC8044180
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8077

Références

Lancet. 2003 May 31;361(9372):1881-93
pubmed: 12788587
Endocrine. 2018 Oct;62(1):3-13
pubmed: 30128958
Therap Adv Gastroenterol. 2020 Dec 8;13:1756284820977402
pubmed: 33343707
N Engl J Med. 2019 Aug 29;381(9):852-861
pubmed: 31461595
Eur J Endocrinol. 2008 Dec;159(6):811-7
pubmed: 18819943
QJM. 2002 Feb;95(2):79-82
pubmed: 11861954
Am J Gastroenterol. 2012 Jul;107(7):991-1000
pubmed: 22613905
World J Gastroenterol. 2009 Jun 21;15(23):2834-8
pubmed: 19533804
Curr Mol Pharmacol. 2018;11(1):51-71
pubmed: 28240194
Therap Adv Gastroenterol. 2017 Nov;10(11):829-836
pubmed: 29147134
Aliment Pharmacol Ther. 2003 Mar 1;17(5):643-50
pubmed: 12641512
J Clin Endocrinol Metab. 2010 Feb;95(2):545-51
pubmed: 20016050
J Clin Gastroenterol. 2019 Apr;53(4):e142-e149
pubmed: 29351154
F1000Res. 2018 Jul 9;7:
pubmed: 30026921
Am J Gastroenterol. 1989 Oct;84(10):1302-5
pubmed: 2801683
Am J Gastroenterol. 2005 May;100(5):1174-84
pubmed: 15842596
Ann Endocrinol (Paris). 2017 Dec;78(6):490-494
pubmed: 29174931
J Clin Endocrinol Metab. 2007 Oct;92(10):3912-22
pubmed: 17684047
J Clin Endocrinol Metab. 2015 Feb;100(2):407-16
pubmed: 25419882
Minerva Gastroenterol Dietol. 2013 Sep;59(3):241-59
pubmed: 23867945
Psychoneuroendocrinology. 2016 Oct;72:80-6
pubmed: 27388687
Gut. 2014 Aug;63(8):1293-9
pubmed: 24153250
FASEB J. 2016 Feb;30(2):971-82
pubmed: 26581598
Therap Adv Gastroenterol. 2020 Apr 9;13:1756284820910630
pubmed: 32313554
World J Gastroenterol. 2015 Jul 14;21(26):8103-9
pubmed: 26185382
J Clin Endocrinol Metab. 2009 Dec;94(12):4882-90
pubmed: 19858318
Gastroenterology. 2000 Sep;119(3):654-60
pubmed: 10982758
Trends Endocrinol Metab. 2019 Aug;30(8):479-490
pubmed: 31257166
Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):749-58
pubmed: 18611115

Auteurs

L Quénéhervé (L)

INSERM, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France.
Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, Nantes, France.

D Drui (D)

Department of Endocrinology, l'Institut du Thorax, CHU Nantes, 44400, Nantes, France.

J Blin (J)

INSERM, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France.
Department of Biology, Laboratory of Clinical Biochemistry, CHU Nantes, 9 Quai Moncousu, 44000, Nantes, France.

M Péré (M)

Biostatistics Unit, Research Board, CHU Nantes, Nantes, France.

E Coron (E)

INSERM, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France.
Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, Nantes, France.

G Barbara (G)

Department of Medical and Surgical Sciences, Centre for Applied Biomedical Research, University of Bologna, IRCCS S. Orsola, Bologna, Italy.

M R Barbaro (MR)

Department of Medical and Surgical Sciences, Centre for Applied Biomedical Research, University of Bologna, IRCCS S. Orsola, Bologna, Italy.

B Cariou (B)

Department of Endocrinology, CNRS, INSERM, l'Institut du Thorax, CHU Nantes, Université de Nantes, 44400, Nantes, France.

M Neunlist (M)

INSERM, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France.
Institut des Maladies de l'Appareil Digestif, IMAD, CHU Nantes, Hôpital Hôtel-Dieu, Nantes, France.

D Masson (D)

INSERM, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France.
Department of Biology, Laboratory of Clinical Biochemistry, CHU Nantes, 9 Quai Moncousu, 44000, Nantes, France.

K Bach-Ngohou (K)

INSERM, TENS, The Enteric Nervous System in Gut and Brain Diseases, IMAD, University of Nantes, Nantes, France. kalyane.bach@chu-nantes.fr.
Department of Biology, Laboratory of Clinical Biochemistry, CHU Nantes, 9 Quai Moncousu, 44000, Nantes, France. kalyane.bach@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH